• Profile

Clinicopathological implications of the expression of vascular endothelial growth factor and programmed cell death ligand 1 in clear cell renal cell carcinoma

Human Pathology Apr 07, 2020

Lee KS, et al. - Researchers compared combined anti-VEGF/anti-PD-L1 targeted therapy synergistically improves treatment outcomes in advanced renal cell carcinoma (RCC) with anti-PD-L1 or anti-VEGF monotherapy. The expression of VEGF and PD-L1 (SP142) were examined in a retrospective cohort of 513 patients with clear cell (cc) RCC. This study eanalyzed PD-L1 expression on tumor cells and immune cells by immunohistochemistry (IHC) with a positive threshold value of ≥ 1%. The results suggest that tumors with positivity for both antibodies revealed the worst recurrence-free survival, and double positivity independently prognosticated tumor recurrence in ccRCC. This research serves comprehensive and basic information about VEGF and PD-L1 expression for new combined therapy in primary ccRCC.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free.
  • 55 lakhs+ doctors trust M3 globally

  • Nonloggedininfinity icon
    Unlimited access to original articles by experts
  • Nonloggedinlock icon
    Secure: we never sell your data
  • Signing up takes less than 2 mins
Try M3 India / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen